Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Why ResMed (RMD) Stock Is Trading Up Today

July 02, 2026 at 15:35 PM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

RMD Cover Image

What Happened?

Shares of medical device company ResMed (NYSE: RMD) jumped 3.7% in the afternoon session after it was added to Goldman Sachs' APAC Conviction List, signaling renewed confidence from the investment bank.

This addition reflects renewed optimism about the company's patient base growth and overall momentum, particularly with its fourth-quarter fiscal 2026 results expected in August. The positive sentiment was also part of a broader trend, as the healthcare sector has seen recent gains. Goldman Sachs' action is seen by investors as a strong endorsement of ResMed's long-term growth trajectory, despite potential headwinds in the sector.

The shares were trading at $209.27, up 4.1% from the previous close.

Is now the time to buy ResMed? Access our full analysis report here, it’s free.

What Is The Market Telling Us

ResMed’s shares are not very volatile and have only had 2 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.

The previous big move we wrote about was 15 days ago when the stock dropped 4.5% on the news that Morgan Stanley downgraded the stock to Equalweight from Overweight and lowered its price target.

The investment firm cut its price target on the shares to $230 from $286. The analyst cited several concerns, including limits to near-term profit margin growth and modest earnings expectations. The downgrade also reflected worries about competitor Philips potentially re-entering the U.S. market for PAP devices, which are used to treat sleep apnea.

Additionally, Morgan Stanley noted potential negative effects from the growing use of GLP-1 weight-loss drugs, which may reduce the need for sleep apnea treatments in some patients.

ResMed is down 14.5% since the beginning of the year, and at $209.27 per share, it is trading 28.8% below its 52-week high of $293.73 from August 2025. Investors who bought $1,000 worth of ResMed’s shares 5 years ago would now be looking at only $835.31.

ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.

These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article